Collegium Pharmaceutical IncCOLL
Price$21.84Intrinsic value$29.0833% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $29.08median of 5 methods · middle span $28-$46based on filings through 30 Jun 2026
Market Price $21.84Price as of 1 Oct 2026
Margin of Safety +33.1%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: -10.7%/yr (balance of the path).-7.8% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 6-8.0%Yr 7-5.2%Yr 8-2.5%Yr 90.3%Yr 103.0%
-10.7% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 1 window (5y) (limited history)17.9%
Discount rate (cost of equity) 8.7%
Volatility vs market (adjusted beta)0.84

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetCollegium Pharmaceutical IncCOLLHealth Care
Valuation
P/E17.6×
P/S0.9×
P/B2.7×
EV / Revenue1.7×
EV / EBITDA3.7×
Profitability
Gross margin60.0%
Operating margin19.5%
Net margin5.9%
FCF margin40.6%
Returns
ROE15.4%
ROA2.2%
ROIC4.8%
Growth
Revenue growth (YoY)28.0%
5-yr fwd EPS growth-7.8%
Financial strength
Debt / Equity2.59×
Current ratio1.03×
Altman Z-Score0.8
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.